Can Ozempic (Semaglutide) Be Used in Graves Disease?
Ozempic (semaglutide) is not contraindicated in patients with Graves disease and can be used, but requires careful thyroid function monitoring and potential levothyroxine dose adjustments if the patient is on thyroid replacement therapy. 1
Contraindications and Safety Profile
The FDA-approved contraindications for Ozempic are specific and do not include Graves disease 1:
- Absolute contraindications include personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 1
- Prior serious hypersensitivity reaction to semaglutide 1
Graves disease itself is not listed as a contraindication, and the safety profile of semaglutide shows no specific concerns for autoimmune thyroid conditions 2.
Dosing Recommendations
Standard semaglutide dosing applies for patients with Graves disease 3, 1:
- Initial dose: 0.25 mg subcutaneously once weekly for 4 weeks (this is a titration dose, not therapeutic) 3, 1
- Maintenance dose: Increase to 0.5 mg once weekly after the initial 4-week period 3, 1
- Maximum dose: May escalate to 1.0 mg once weekly after at least 4 weeks on 0.5 mg if additional glycemic control is needed 3, 1
- Administration: Can be given any day of the week, with or without meals 3, 1
The gradual dose escalation is critical to minimize gastrointestinal adverse events (nausea, vomiting, diarrhea), which occur in approximately 40% and 16% of patients respectively 4.
Critical Monitoring Requirements
For Patients with Treated Graves Disease on Levothyroxine
This is the most important clinical consideration: Patients with a history of Graves disease who are on levothyroxine replacement require close thyroid function monitoring when starting semaglutide 5, 6:
- Mechanism of concern: Semaglutide-induced weight loss can lead to iatrogenic hyperthyroidism in patients on fixed-dose levothyroxine, as the dose becomes supratherapeutic for the reduced body weight 5
- Drug interaction: Oral semaglutide increases total T4 exposure by 33% when co-administered with levothyroxine, though this effect is less pronounced with subcutaneous formulations 6
- Monitoring schedule: Check TSH and free T4 at baseline, then every 4-6 weeks during active weight loss phase 5
- Dose adjustment: Anticipate need for levothyroxine dose reduction as weight decreases; the standard levothyroxine dosing of 1.6 mcg/kg will require recalculation based on new body weight 5
For Patients with Active Untreated Graves Disease
If a patient has active, untreated Graves hyperthyroidism, this should be controlled first before initiating semaglutide 7:
- First-line treatment: Thiamazole (methimazole) or carbimazole are preferred antithyroid drugs, with initial dosing of 0.4-0.8 mg/kg/day (maximum 30 mg) 8, 7
- Propylthiouracil is contraindicated except in first trimester pregnancy due to hepatotoxicity risk 7
- Treatment duration: Typically 12-18 months to achieve remission 7
- Monitoring during antithyroid therapy: TSH and free T4 monthly until euthyroid, then every 2-3 months 7
Special Considerations
Thyroid C-Cell Tumor Risk
The boxed warning for semaglutide regarding thyroid C-cell tumors is based on rodent data and applies to medullary thyroid carcinoma specifically, not Graves disease 1, 2:
- Graves disease is an autoimmune condition causing hyperthyroidism via TSH receptor antibodies 8
- This is mechanistically distinct from medullary thyroid carcinoma (which arises from parafollicular C-cells) 1
- No increased risk of thyroid cancer has been definitively established in humans using GLP-1 receptor agonists 2
Renal and Hepatic Function
No dose adjustment is required for renal or hepatic impairment, including end-stage renal disease 1. This is relevant as some patients with Graves disease may have concurrent organ dysfunction.
Perioperative Management
If thyroidectomy is planned for definitive Graves treatment 7:
- Hold semaglutide at least 7 days before surgery to reduce aspiration risk from delayed gastric emptying 3
- Ensure euthyroid status before any surgical intervention 7
Common Pitfalls to Avoid
- Failing to monitor thyroid function in patients on levothyroxine who lose significant weight with semaglutide—this can lead to iatrogenic thyrotoxicosis 5
- Confusing medullary thyroid carcinoma risk (the actual contraindication) with Graves disease (not a contraindication) 1
- Not adjusting levothyroxine dosing based on new body weight after semaglutide-induced weight loss 5
- Starting semaglutide in uncontrolled hyperthyroidism—achieve euthyroid state first with antithyroid medications 7